Vimarsana
Biggest News Aggregation in the World

Efficacy Outcomes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Efficacy Outcomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Efficacy Outcomes Today - Breaking & Trending Today

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke - Vimarsana News

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

This clinical trial assesses the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for patients wit

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023 - Vimarsana News

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

/PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell...

Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC - Vimarsana News

Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC

Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial | Infectious Diseases | JAMA - Vimarsana News

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial | Infectious Diseases | JAMA

This randomized clinical trial compares the efficacy and safety of letermovir vs valganciclovir prophylaxis for cytomegalovirus (CMV) disease in CMV-seronegativ

LivaNova PLC: LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting - Vimarsana News

LivaNova PLC: LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place December